Anti-PD-1 antibody nivolumab is recommended for treating melanoma 11, 25, renal cell carcinoma (RCC)26, Hodgkin's lymphoma 27, 28, urine epidermal cancer 29, MSI-H colon cancer 30 and hepatocellular carcinoma 31. This evidence concerns the gene PDCD1 and melanoma.